A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer

The purpose of this study is to find out whether BMS986365 in combination with degarelix, given before standard surgical treatment (radical prostatectomy), is a safe and effective treatment that causes few or mild side effects for people who have localized high-risk prostate cancer.

Trial Details

NCT ID
NCT07335796
Phase
PHASE2
Sponsor
Memorial Sloan Kettering Cancer Center
Status
RECRUITING
Cancer Type
Castration-Resistant (CRPC) Prostate Cancer
Interventions
  • BMS-986165
  • Degarelix
Locations (sample)
  • Basking Ridge, New Jersey, United States|40.70621,-74.54932
  • Montvale, New Jersey, United States|41.04676,-74.02292
  • Commack, New York, United States|40.84288,-73.29289
  • Harrison, New York, United States|40.96899,-73.71263
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Participant or participant's legally authorized representative (LAR) is willing and able to provide written informed consent and privacy authorizat…
  • Individuals with prostate cancer 18 years of age and above
  • Histological or cytological evidence of prostate cancer
  • Documented high-risk localized prostate cancer based on one or more of the following NCCN criteria:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Castration-Resistant (CRPC) Prostate Cancer Trials on Trialify →